Dr. Krzysztof A Fidelis leads a research lab focused on improving our understanding of macromolecule structures, which are crucial for biology and medicine. His work, primarily through the Critical Assessment of Structure Prediction (CASP) program, involves using advanced computational techniques, including deep learning, to predict protein structures. By participating in a global research community, the lab aims to enhance methods for modeling complex biological systems relevant to drug design and disease mechanisms.

The lab led by Prof. Oliver Fiehn at UC Davis focuses on enhancing the field of metabolomics, which studies the unique chemical fingerprints that cellular processes leave behind. One of their main projects aims to create a cloud-based database called LC-BinBase that standardizes the analysis of metabolomics and lipidomics data, enabling better reproducibility across different laboratories and instruments. By developing advanced algorithms and offering workshops for collaboration, the lab is striving to improve the quality and usability of metabolic data for biomedical researchers.

Megan Y Dennis's lab at UC Davis focuses on understanding how human gene duplications influence neurodevelopment and are linked to various neurological disorders. Their research employs innovative techniques like CRISPR and utilizes zebrafish as a model organism to study the effects of duplicated genes on brain development. Additionally, the lab is developing improved computational approaches to identify genetic variants associated with neurodevelopmental disorders, particularly in complex regions of the human genome.

Dr. Yuanpei Li's lab focuses on developing innovative nanotherapeutics designed to improve treatment for brain cancers, particularly aggressive pediatric tumors like diffuse midline glioma (DMG) and high-grade gliomas in dogs. Through advanced nanoparticle technology, they aim to enhance drug delivery across the challenging blood-brain barrier and overcome resistance to current therapies. By studying both human and canine models, the lab works to create effective treatments that could significantly improve patient outcomes.

Dr. David E. Olson's lab focuses on discovering new treatments for addiction by developing non-hallucinogenic compounds that can promote changes in brain structure and function. These compounds, known as psychoplastogens, could offer therapeutic benefits for conditions like substance use disorders without the side effects of hallucinations. The lab employs innovative techniques to rapidly identify and evaluate these promising molecules.

The lab led by Dr. Kit S. Lam focuses on developing innovative therapeutic strategies to enhance cancer treatment, specifically by targeting the tumor microenvironment using transformable nanoparticles. By utilizing a unique platform that adjusts its structure in response to specific tumor markers, the lab aims to deliver treatments that activate the immune system against cancer while minimizing damage to normal tissues. Their research is particularly relevant to the treatment of non-small cell lung cancer.